

Medicines Management FAQs – COVID19

Should I change the way I manage patients with severe asthma during COVID19?

NICE have published a rapid guideline about managing severe asthma during COVID19: [NICE \(NG166\) COVID-19 rapid guideline: severe asthma](#)

Note advice to prescribe enough asthma medicines to meet the patient's clinical needs for no more than 30 days' treatment. For inhalers this depends on the type of inhaler and the number of doses in the inhaler. **Prescribing larger quantities of asthma medicines puts the supply chain at risk. See [BTS advice](#)**

Patients should continue with their usual treatment and if they develop symptoms and signs of exacerbation, they should follow their personalised asthma action plan and start a course of oral corticosteroids if clinically indicated.

GSK have produced an online asthma control test to help patients keep track of how well their asthma is being controlled: <https://www.asthmacontroltest.com/>